Dave Ricks
Chair & CEO, Eli Lilly and Company. On 2 shows, 3 appearances. The Shows tab opens the full record on each.
executiveoperatorWikipedia ↗Instagram ↗
David A. Ricks has led Eli Lilly as CEO since 2017, overseeing its expansion into one of the world's most valuable pharmaceutical companies driven by blockbuster diabetes and obesity therapies like Mounjaro and Zepbound. Beyond Lilly, he serves on the board of directors of Adobe and the Purdue University Board of Trustees.
2shows
3appearances
122statements
59resolved
33supported
9contradicted
56%fully supported
1said about them ↓ Everything Dave Ricks said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Dave Ricks predicts competitor's GLP-1 dementia study likely won't be positive
“Our competitor is going to read out a study in a few months on dementia risk. It probably won't be positive. That's my guess, but it will probably be in the right direction.”
Dave Ricks: Low-dose GLP-1s could eventually be used to extend healthspan
“I think we're going to get to a point. We're taking pretty low doses for most people, say over 60, 58. It's not a terrible idea. It may help you live longer.”
Dave Ricks claims anti-fat, high-carb diets drove US obesity growth
“The anti-fat, high-carb diets, which we were feeding people for 30 years, and I think most people don't believe in that anymore, but it led to a big part of the obesity curve, glycemic index kind of thing.”
Dave Ricks supports reducing direct-to-consumer pharmaceutical advertising
“Well, I would be for a system where we don't have nearly as much drug advertising, to be clear.”
Ricks: Eli Lilly's GLP-1 drugs are undefeated in chronic disease trials
“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”
Ricks: Three-year Mounjaro trial showed 94% reduction in diabetes diagnoses
“We just read that study out with Manjaro, which showed that three years on our drug, 94% fewer new diagnosis of outright diabetes.”
Dave Ricks: Medicare rules prohibit covering weight-loss drugs unless patients have diabetes
“If you're say on Medicare, currently the rule of the federal government is they won't pay. For these medications. You have to get diabetes before you can get the drug.”
Under 5% of obese adults reach healthy weight via lifestyle changes alone
“Some studies show like less than five percent of people can reach a healthy body weight on diet and exercise once they're obese.”
Dave Ricks expects steady-state GLP-1 net pricing around $3,000 to $4,000 annually
“Probably net pricing for us, you know, is going to be something like three, 4000 dollars a year in the steady state per person, but I think we'll create more value than that. We'll save the system more money than that per year per user.”
Eli Lilly retains only one-third of gross drug prices after PBM cuts
“Two thirds of actually our gross price goes to PBMs and insurance companies. So of the gross price that's often quoted, the net for us is about a third of that.”
Dave Ricks: AI's primary drug discovery value is eliminating bad ideas
“It's a co-pilot model where the machine can do predictions. Probably now where we see the most value is Eliminating bad ideas that humans don't see, but in hindsight look obvious. So like, cause you can integrate a lot of multi source data and say the probabil…”
Ricks: Eli Lilly is building pharma's largest biological supercomputer
“Building a supercomputer on our, on-prem for us, really just to run proprietary drug discovery models. We think it's the biggest biologically focused supercomputer there is. And certainly the biggest pharma's done. Yes. With B 300 latest chipset.”
Ricks: Developing a drug costs $4B, with over 60% spent in Phase 3
“The final stage of testing, the average drug costs three and a half, four billion to make more than 60% of that is the last step.”
Ricks: US cancer trial enrollment is 4% versus over 25% in Spain
“Only four percent of patients who have cancer in the US are in clinical trials, whereas in Spain and Australia, it's over 25%.”
Ricks: Lilly develops clinical drugs in under 7 years versus industry average
“Drug development time in the industry, It's about 10 years in the clinic, a little less right now. We're running a little less than seven at Lilly”
Ricks: Current GLP-1 drug pricing will fall amid competition and pressure
“And the current pricing isn't going to stay. Let's be honest. There'll be more competition. The government wants to lower our prices.”
Ricks: Non-Lilly large pharma multiples are at a 20-year low
“If you look at the large cap farmers, not Lilly, but the other ones, the multiples, the most compressed it's been in 20 years. If you look at biotech, the XBI, I think half of the XBI is trading below cash. And then if you look at. Venture. Half of the rounds …”
Ricks: Drugs lose 97% of their pricing when patents expire
“Typically a generic event, you'll lose 97% of your pricing the day your patent expires.”
Ricks: Most major hospital systems have failed price transparency compliance
“Compliance is terrible. Most major hospital systems have not complied. Or if they have, they put on a website somewhere a coded database that is impossible to interpret with ICD-X codes and price points that consumers cannot digest.”
Ricks: Lilly conducts early clinical trials faster and cheaper than any biotech
“There is no doubt in my mind. We are faster, more robust, probably cheaper than actually every biotech out there trying to do their own early phase clinical trials.”
Ricks: China had Pfizer-BioNTech vaccine rights but never approved it
“They had rights to the BioNTech-Pfizer vaccine for almost the entirety of their pandemic. They never approved it.”
Ricks: Virtually no generic pharmaceuticals are manufactured in the US
“There are no generics manufactured in the U.S. Really.”
The other half of the tape: Dave Ricks's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode across the shows. every mention, with the transcript →
Who brings them up most Chamath Palihapitiya 1
Every mention by year
tap a year for its mentions
All-In 1
2024 1 mention in 1 episode
One line per show, most statements first. The link opens Dave's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
| ALL-INLEDGER | Chair & CEO, Eli Lilly and Company | 2 | 71 | 55% 16/29 | full record on All-In → |
 CHEEKY PINTLEDGER | Chair & CEO, Eli Lilly and Company | 1 | 51 | 57% 17/30 | full record on Cheeky Pint → |